RIT1

Chr 1AD

Ras like without CAAX 1

Key regulator of both differentiation and survival of T-lymphocytes during thymocyte development in mammals. Essential in controlling the responsiveness of hematopoietic stem cells to chemotactic signals by modulating the expression of the receptors CCR7 and CCR9, which direct the movement of progenitor cells from the bone marrow to the thymus (PubMed:27959755). Is a regulator of IL2 promoter and enhances IL2 expression in activated CD4(+) T-lymphocytes (PubMed:16809611). Tumor-suppressor that represses transcription through direct, TFCOUP2-independent binding to a GC-rich response element (By similarity). May also function in the P53-signaling pathway (By similarity)

Primary Disease Associations & Inheritance

Noonan syndrome 8MIM #615355
AD
UniProtImmunodeficiency 49, severe combined
UniProtIntellectual developmental disorder with speech delay, dysmorphic facies, and T-cell abnormalities
438
ClinVar variants
54
Pathogenic / LP
0.13
pLI score
2
Active trials
Clinical SummaryRIT1
Population Constraint (gnomAD)
Constrained for loss-of-function variants (OE-LoF 0.28) despite low pLI — interpret in context.
📋
ClinVar Variants
54 Pathogenic / Likely Pathogenic· 207 VUS of 438 total submissions
💊
Clinical Trials
2 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.65LOEUF
pLI 0.133
Z-score 2.51
OE 0.28 (0.140.65)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
2.08Z-score
OE missense 0.52 (0.430.63)
75 obs / 145.4 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.28 (0.140.65)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.52 (0.430.63)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.98
01.21.6
LoF obs/exp: 4 / 14.2Missense obs/exp: 75 / 145.4Syn Z: 0.09

ClinVar Variant Classifications

438 submitted variants in ClinVar

Classification Summary

Pathogenic32
Likely Pathogenic22
VUS207
Likely Benign139
Benign15
Conflicting19
32
Pathogenic
22
Likely Pathogenic
207
VUS
139
Likely Benign
15
Benign
19
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
18
14
0
32
Likely Pathogenic
0
19
3
0
22
VUS
7
172
27
1
207
Likely Benign
0
1
58
80
139
Benign
0
1
13
1
15
Conflicting
19
Total721111582434

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

RIT1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

RIT1-related Noonan syndrome

definitive
ADGain Of FunctionAltered Gene Product Structure
Dev. DisordersSkinCardiac
G2P ↗
missense variant

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Noonan syndrome 8

MIM #615355

Molecular basis of disorder known

Autosomal dominant
Clinical Literature
Landmark / reviewRecent case evidence
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
Europe PMC